246 related articles for article (PubMed ID: 36880426)
1. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
[TBL] [Abstract][Full Text] [Related]
4. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
[TBL] [Abstract][Full Text] [Related]
5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
Martini G; Ciardiello D; Dallio M; Famiglietti V; Esposito L; Corte CMD; Napolitano S; Fasano M; Gravina AG; Romano M; Loguercio C; Federico A; Maiello E; Tuccillo C; Morgillo F; Troiani T; Di Maio M; Martinelli E; Ciardiello F
Int J Cancer; 2022 Aug; 151(3):473-480. PubMed ID: 35429341
[TBL] [Abstract][Full Text] [Related]
8. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y
BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
[TBL] [Abstract][Full Text] [Related]
10. China special issue on gastrointestinal tumors-Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
Quan M; Chen J; Chen Z; Hai Y; Zhou Y; Chao Q; Chen C; Li H; Wang M; Gao Y
Int J Cancer; 2023 Dec; 153(11):1877-1884. PubMed ID: 37163613
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
Lv ZC; Ning JY; Chen HB
Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
[TBL] [Abstract][Full Text] [Related]
12. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
13. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Sobrero A; Lenz HJ; Eng C; Scheithauer W; Middleton G; Chen W; Esser R; Nippgen J; Burris H
Oncologist; 2021 Feb; 26(2):e261-e269. PubMed ID: 33191588
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
[TBL] [Abstract][Full Text] [Related]
15. Skin Toxicity as Predictor of Survival in Refractory Patients with
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Normanno N; Avallone A; Latiano T; Maiello E; Pietrantonio F; Cremolini C; Santabarbara G; Pinto C; Troiani T; Martinelli E; Ciardiello F; Martini G
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830870
[TBL] [Abstract][Full Text] [Related]
16. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated
Napolitano S; Martini G; Ciardiello D; Di Maio M; Normanno N; Avallone A; Martinelli E; Maiello E; Troiani T; Ciardiello F
Front Oncol; 2022; 12():940523. PubMed ID: 35832541
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Vidal J; Fernández-Rodríguez MC; Casadevall D; García-Alfonso P; Páez D; Guix M; Alonso V; Cano MT; Santos C; Durán G; Elez E; Manzano JL; Garcia-Carbonero R; Ferreiro R; Losa F; Pineda E; Sastre J; Rivera F; Bellosillo B; Tabernero J; Aranda E; Salazar R; Montagut C;
Clin Cancer Res; 2023 Jan; 29(2):379-388. PubMed ID: 36074154
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
Masuishi T; Tsuji A; Kotaka M; Nakamura M; Kochi M; Takagane A; Shimada K; Denda T; Segawa Y; Tanioka H; Hara H; Sagawa T; Watanabe T; Takahashi T; Negoro Y; Manaka D; Fujita H; Suto T; Takeuchi M; Ichikawa W; Fujii M
Br J Cancer; 2020 Nov; 123(10):1490-1495. PubMed ID: 32863385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
